Pricing

Astellas Pharma Inc

0 followers ·
NEW YORK NY
Astellas Pharma is based out of New York. Astellas Pharma Inc. engages in the manufacture, marketing, and import/export of pharmaceutical products. It primarily focuses on the development of products in the areas of urology, immunology, inflammation, central nervous system, pain, diabetes, cancer, cardiovascular, and dermatology, as well as infectious diseases, including viral diseases. The company's products include Prograf, an immunosuppressant to prevent rejection in organ transplants; Protopic for the treatment of atopic dermatitis; Vesicare for the treatment of overactive bladder; Harnal for the treatment of benign prostatic hyperplasia; and Funguard, an antifungal agent. Its products also comprise Geninax, an oral quinolone antibacterial agent for respiratory tract and otorhinolaryngological infection pathogens; Celecox, a selective COX-2 lnhibitor for the rheumatoid arthritis; Lipitor for the treatment of hypercholesterolemia; Micardis for the treatment for hypertension; Gaster for the treatment for peptic ulcers and gastritis; Luvox, an antidepressant; Myslee for the treatment of insomnia; Cefzon, an oral cephalosporin antibiotic; Seroquel, an antipsychotic agent used for the treatment of schizophrenia; Dorner for chronic arterial occlusion; Nasea, a antagonist; and Targocid, a glycopeptide antibiotic. In addition, the company offers Lexiscan and Adenoscan, which are pharmacologic stress agents; AMEVIVE for the treatment of psoriasis; Vaprisol for euvolemic hyponatremia; AmBisome, an antifungal agent; Eligard for advanced prostate cancer; Locoid, a topical corticosteroid; Zineryt for acne; and Locobase for dry skin. It has licensing agreement with CoMentis, Inc. to research, develop, and commercialize beat- secretase inhibitors, including CTS-21166 for the treatment of Alzheimer's disease. Astellas Pharma operates in Japan, North America, Europe, and Asia. The company was founded in 1923 and is headquartered in Tokyo, Japan. The firm has no submitted 13F filings and does not appear to be an investment advisor.

Contact Info

Contact information is taken directly from publicly disclosed SEC filings.

Astellas Pharma Inc
60 WALL STREET
NEW YORK NY    10005

Business Phone: 212-250-9100

Recent SEC Filings

Filing Date
F-6EF 2019-11-22
F-6EF 2017-12-21
F-6 POS 2017-09-29
F-6EF 2014-10-15
F-6 POS 2014-04-02
F-6 POS 2014-03-24
F-6 POS 2014-03-24
F-6 POS 2014-03-20
F-6 POS 2013-05-13
F-6EF 2013-02-13